Wechselwirkungen · Forxiga
Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-125349 · Präparat HOS-096051
In interaction studies conducted in healthy subjects, using mainly a single-dose design, dapagliflozin did not alter the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P-gp substrate) or warfarin (S-warfarin, a CYP2C9 substrate), or the anticoagulatory effects of warfarin as measured by INR. Combination of a single dose of dapagliflozin 20 mg and simvastatin (a CYP3A4 substrate) resulted in a 19% increase in AUC of simvastatin and 31% increase in AUC of simvastatin acid. The increase in simvastatin and simvastatin acid exposures are not considered clinically relevant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glimepiride (HOS-112373) dapagliflozin (HOS-125333) hydrochlorothiazide (HOS-086937) simvastatin (HOS-086158) digoxin (HOS-086172) pioglitazone (HOS-089663) bumetanide (HOS-125088) valsartan (HOS-088810) sitagliptin (HOS-117222) warfarin (HOS-085950) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-12T16:11:00Z · SHA-256 a32f3f48ad3ffeffd85467179c7cd7d2f4f8e65c471ebf5e9fcd92a61c71299a · Passage 361cd8370e4286c31ed41c717e3805d0a94f6e3e55d103eb23354b89f43108f1 · Zeichen 2486–3139 im Abschnitt